<DOC>
	<DOCNO>NCT00543790</DOCNO>
	<brief_summary>This first multiple-dose study human PRA-027 . This study provide assessment safety , tolerability , pharmacokinetics ( drug absorb , metabolize excrete body ) pharmacodynamics ( measure whether drug active body ) PRA-027 administration 28 day oral dos woman childbearing potential ( cycle ) postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Inclusion Criteria All Women Healthy , nonsmoker smoker few 10 cigarette ( half pack ) per day able abstain tobacco throughout time clinical facility . Inclusion Criteria Cycling Women Aged 18 45 year , must breastfeed , pregnant , recent ( within 90 day pretreatment period day 1 ) history pregnancy , history regular menstrual cycle ( 21 35 day duration ) . Inclusion Criteria Postmenopausal Women Aged 35 65 year , menopause may natural due surgery , natural amenorrhea must begin age 55 year initiate least 6 month study day 1 . Women hysterectomy complex simple ovarian cyst great 3 cm diameter . History drug abuse ( within 6 month ) alcoholism ( within 12 month ) . History female infertility .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>